Myelodysplastic Syndromes — Lower-Risk (IPSS-R very low / low / intermediate) · line 1 · ESA (epoetin alfa or darbepoetin) — MDS-LR symptomatic anemia 1L
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-ESA-MDS-LR |
| ID | IND-MDS-LR-1L-ESA |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MDS-LR |
| Sources | SRC-ESMO-MDS-2021 SRC-NCCN-AML-2025 |
Notes
Standard track for MDS-LR symptomatic anemia. Treatment intent: cytopenia management + symptom control; does NOT alter natural history. AlloHCT not indicated for MDS-LR (deferred until / unless IPSS-R progression). STUB — requires clinical co-lead signoff.
Used By
Algorithms
ALGO-MDS-LR-1L- ALGO-MDS-LR-1L